ArticleAntimicrobial agents and chemotherapy2012
Identification of BPR3P0128 as an inhibitor of cap-snatching activities of influenza virus.
Article in Antimicrobial agents and chemotherapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- High-throughput screening for identification of influenza a inhibitors using a cell-based immunofluorescence assay.Antiviral research · 2025Article
- The multiple roles of viral 3DVirulence · 2024Review
- BPR3P0128, a non-nucleoside RNA-dependent RNA polymerase inhibitor, inhibits SARS-CoV-2 variants of concern and exerts synergistic antiviral activity in combination with remdesivir.Antimicrobial agents and chemotherapy · 2024Article
- A Noble Extract ofMicroorganisms · 2024Article
- High-Throughput cell-based immunofluorescence assays against influenza.SLAS discovery : advancing life sciences R & D · 2024Article
- Biochemical characterization of mRNA capping enzyme from Faustovirus.RNA (New York, N.Y.) · 2023Article
- Virtual Screening and Molecular Dynamics Simulation Study of Influenza Polymerase PB2 Inhibitors.Molecules (Basel, Switzerland) · 2021Article
- Antiviral Activity of a Llama-Derived Single-Domain Antibody against Enterovirus A71.Antimicrobial agents and chemotherapy · 2020Article
- Identification of pyrvinium pamoate as an anti-tuberculosis agentEmerging microbes & infections · 2020Article
- Structure of a functional cap-binding domain in Rift Valley fever virus L protein.PLoS pathogens · 2019Article
- The PA Endonuclease Inhibitor RO-7 Protects Mice from Lethal Challenge with Influenza A or B Viruses.Antimicrobial agents and chemotherapy · 2017Article
- Influenza A Virus Nucleoprotein: A Highly Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target.Current topics in medicinal chemistry · 2017Review
- Amino acid substitutions V63I or A37S/I61T/V63I/V100A in the PA N-terminal domain increase the virulence of H7N7 influenza A virus.Scientific reports · 2016Article
- The Influenza Virus Polymerase Complex: An Update on Its Structure, Functions, and Significance for Antiviral Drug Design.Medicinal research reviews · 2016Review
- An extract from Taxodium distichum targets hemagglutinin- and neuraminidase-related activities of influenza virus in vitro.Scientific reports · 2016Article
- A Novel Endonuclease Inhibitor Exhibits Broad-Spectrum Anti-Influenza Virus Activity In Vitro.Antimicrobial agents and chemotherapy · 2016Article
- Inhibition of endosomal fusion activity of influenza virus by Rheum tanguticum (da-huang).Scientific reports · 2016Article
- Atomic Structure and Biochemical Characterization of an RNA Endonuclease in the N Terminus of Andes Virus L Protein.PLoS pathogens · 2016Article
- Using mutagenesis to explore conserved residues in the RNA-binding groove of influenza A virus nucleoprotein for antiviral drug development.Scientific reports · 2016Article
- Establishment of a High-Throughput Assay to Monitor Influenza A Virus RNA Transcription and Replication.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to identify the antiviral mechanism of a novel compound, BPR3P0128. From a large-scale screening of a library of small compounds, BPR3P compounds were found to be potent inhibitors of influenza viral replication in Madin-Darby canine kidney (MDCK) cells. BPR3P0128 exhibited inhibitory activity against both influenza A and B viruses. The 50% inhibitory concentrations were in the range of 51 to 190 nM in MDCK cells, as measured by inhibition-of-cytopathic-effect assays. BPR3P0128 appeared to target the viral replication cycle but had no effect on viral adsorption. The inhibition of cap-dependent mRNA transcription by BPR3P0128 was more prominent with a concurrent increase in cap-independent cRNA replication in a primer extension assay, suggesting a role of BPR3P0128 in switching transcription to replication. This reduction in mRNA expression resulted from the BPR3P-mediated inhibition of the cap-dependent endoribonuclease (cap-snatching) activities of nuclear extracts containing the influenza virus polymerase complex. No inhibition of binding of 5' viral RNA to the viral polymerase complex by this compound was detected. BPR3P0128 also effectively inhibited other RNA viruses, such as enterovirus 71 and human rhinovirus, but not DNA viruses, suggesting that BPR3P0128 targets a cellular factor(s) associated with viral PB2 cap-snatching activity. The identification of this factor(s) could help redefine the regulation of viral transcription and replication and thereby provide a potential target for antiviral chemotherapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.